Industrial process for the preparation of cariprazine

Patent metadata

Field	Value
Publication number	US-11274087-B2
Application number	US-201716316312-A
Country	US
Kind code	B2
Filing date	Jul 7, 2017
Priority date	Jul 8, 2016
Publication date	Mar 15, 2022
Grant date	Mar 15, 2022

Abstract

In the process of the present invention, cariprazine is prepared by converting (trans-4-amino-cyclohexyl)-acetic acid ethyl ester hydrochloride to trans-4-aminocyclohexyl) acetic acid or its hydrochloride by hydrolysis, from the obtained product with addition of dimethylcarbamoyl derivative as a suitable reagent (trans-4-{[(dimethylamino)carbonyl]amino}cyclohexyl) acetic acid is formed, then the obtained compound is linked to 1-{2,3-dichlorophenyl)˜piperazine in the presence of carboxylic acid activating coupling reagent, and so 1,1-dimethyl-3-[trans-4-(2-oxo-2-(4-(2,3-dichlorophenyl)piperazin-1-yl-ethyl)cyclohexyl] urea is formed, which is converted to cariprazine borane adduct of formula (2) in the presence of reducing agent, and finally the product itself is eliminated directly or is obtained from its salt by a known method. The invention also relates to a group of intermediate compounds that are formed and/or used in the process according to the present invention.

First claim

The invention claimed is:

1. A process for the preparation of cariprazine

comprising:
a) converting (trans-4-amino-cyclohexyl)-acetic acid ethyl ester hydrochloride to (trans-4-aminocyclohexyl) acetic acid or its hydrochloride by hydrolysis,
b) adding a dimethylcarbamoyl derivative as a reagent to the (trans-4-aminocyclohexyl) acetic acid in the presence of an alkaline reagent to form (trans-4 {[(dimethylamino)carbonyl]amino}cyclohexyl) acetic acid,
c) linking (trans-4 {[(dimethylamino)carbonyl]amino}cyclohexyl) acetic acid to 1-(2,3-dichlorophenyl)-piperazine in the presence of a carboxylic acid activating coupling reagent to form 1,1-dimethyl-3-[trans- 4-(2-oxo-2-(4-(2,3-dichlorophenyl)piperazin-1-yl-ethyl)cyclohexyl] urea,
d) converting the 1,1-dimethyl-3-[trans- 4-(2-oxo-2-(4-(2,3-dichlorophenyl)piperazin-1-yl-ethyl)cyclohexyl] urea to the cariprazine borane adduct of formula (2),

in the presence of a reducing agent, and
e) obtaining the cariprazine by elimination or from a cariprazine salt.

2. The process according to claim 1 characterized by carrying out the hydrolysis of (trans-4-amino-cyclohexyl)-acetic acid ethyl ester hydrochloride by basic or acidic hydrolysis.

3. The process according to claim 1 characterized in that (trans-4-{[{dimethylamino)carbonyl]amino}cyclohexyl)-acetic acid is formed with dimethyl-carbamoyl chloride as the reagent.

4. The process according to claim 1 characterized in that the carboxylic acid activating coupling reagent is a dehydrating agent.

5. The process according to claim 1 characterized in that the carboxylic acid activating coupling reagent is carbonyldiimidazole or thionyl chloride.

6. The process according to claim 1 characterized in that the reducing agent is formed in situ from a suitable precursor.

7. The process according to claim 1 characterized in that the reducing agent is a borohydride having a cationic counter ion, a borane, or a complex thereof.

8. The process according to claim 7 characterized in that the borane complex is a complex of borane formed with a Lewis base.

9. The process according to claim 7 characterized in that the cationic counter ion is a positive ion of a metallic element.

10. The process according to claim 1 characterized in that after formation of the cariprazine borane adduct, a cariprazine salt is obtained by decomposition of the cariprazine borane adduct with a Brönsted acid in conventional solvents.

11. The process according to claim 10 characterized in that the Brönsted acid used for decomposition in conventional solvents is hydrogen chloride and the cariprazine salt obtained is cariprazine hydrochloride.

12. The process according to claim 11 characterized in that the cariprazine hydrochloride salt is converted into cariprazine.

13. The process according to claim 1 characterized in that the cariprazine borane adduct is thermally decomposed in conventional solvents to form cariprazine.

14. 1,1-Dimethyl-3-[trans-4-(2-oxo-2-(4-(2,3-dichlorophenyl)piperazin-1-ylethyl)cyclohexyl] urea cariprazine borane adduct of formula (2)

15. The process according to claim 8 characterized in that the borane complex is an ether, a thioether, an amine, or a tetrahydrofuran complex.

16. The process according to claim 9 characterized in that the cationic counter ion is an alkali metal, an alkaline earth metal, an earth metal, or aluminum.

Assignees

• Richter Gedeon Nyrt

Inventors

• Neu József
• Garadnay Sándor
• Szabó Tamás

Classifications

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61K31/495 Primary

  having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title

• C07D295/03

  with the ring nitrogen atoms directly attached to acyclic carbon atoms · CPC title

• C07D295/033

  with the ring nitrogen atoms directly attached to carbocyclic rings · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title